Veeva Systems (NYSE:VEEV) Stock Dropped to “Hold” by Wall Street Zen

Wall Street Zen downgraded shares of Veeva Systems (NYSE:VEEV) from a buy rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Several other brokerages have also recently issued reports on VEEV. Truist Financial upped their price objective on Veeva Systems from $262.00 to $305.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Guggenheim lifted their target price on Veeva Systems from $276.00 to $310.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Raymond James Financial reiterated an “outperform” rating and issued a $225.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Morgan Stanley upped their price target on Veeva Systems from $215.00 to $275.00 and gave the company an “equal weight” rating in a research report on Thursday, August 27th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $330.00 price objective on shares of Veeva Systems in a research note on Tuesday, September 8th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Veeva Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $284.88.

Veeva Systems Price Performance

Shares of VEEV stock opened at $280.95 on Friday. The firm has a fifty day moving average of $243.35 and a two-hundred day moving average of $196.79. The firm has a market cap of $45.49 billion, a P/E ratio of 46.21, a P/E/G ratio of 1.20 and a beta of 0.97. Veeva Systems has a 1-year low of $148.05 and a 1-year high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The business had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. During the same quarter in the prior year, the business posted $1.99 EPS. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, sell-side analysts expect that Veeva Systems will post 6.7 EPS for the current year.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the transaction, the insider directly owned 19,449 shares of the company’s stock, valued at approximately $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Priscilla Hung sold 750 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the sale, the director owned 3,242 shares in the company, valued at $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,750 shares of company stock worth $12,017,360 in the last three months. 10.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VEEV. Czech National Bank bought a new position in shares of Veeva Systems during the second quarter worth about $7,584,000. BNP Paribas increased its holdings in shares of Veeva Systems by 89.3% in the 4th quarter. BNP Paribas now owns 19,239 shares of the technology company’s stock worth $4,308,000 after acquiring an additional 9,077 shares during the period. East Coast Asset Management LLC. bought a new stake in Veeva Systems in the 1st quarter valued at about $1,665,000. WINTON GROUP Ltd bought a new stake in Veeva Systems in the 4th quarter valued at about $3,916,000. Finally, Norges Bank bought a new stake in Veeva Systems in the 4th quarter valued at about $332,412,000. 88.20% of the stock is currently owned by institutional investors.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: AI product launch could improve growth and customer value. Veeva Study Builder Agent can configure Veeva EDC and Data Quality System directly from a clinical-study protocol, potentially reducing manual setup work and enabling studies to be configured in as little as one day. The tool uses customer standards and the CDISC Unified Study Definitions Model to produce faster, more consistent builds. New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
• Positive Sentiment: Recent customer wins support the platform’s competitive position. Oxford Biomedica is adopting Veeva Quality Cloud, while Amgen plans a global deployment of Veeva Vault CRM. These agreements expand Veeva’s presence with large biopharmaceutical customers and could support recurring revenue and cross-selling. How Investors Are Reacting To Veeva Systems Expanding Agentic AI And Winning New Pharma Clients
• Positive Sentiment: Analysts see potential valuation upside. One recent assessment argued that VEEV could be approximately 29% undervalued following the Study Builder Agent launch, suggesting investors may not yet fully reflect the commercial potential of its AI initiatives. Veeva Systems Could Be 29% Undervalued Following Its New AI Study Design Launch
• Neutral Sentiment: Industry growth provides a favorable backdrop. The quality-management software market is projected to grow at an approximately 11.7% annual rate through 2031, potentially expanding Veeva’s addressable market, although the forecast is not company-specific. Quality Management System Software Market Forecasts Growth
• Negative Sentiment: Near-term performance remains a concern. VEEV has declined 2.6% since its latest earnings report, indicating that investors may be seeking stronger forward guidance or additional evidence that AI investments will accelerate results. The stock also trades at a premium valuation, increasing sensitivity to estimates and execution. Veeva Down 2.6% Since Last Earnings Report

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides technology solutions for the life sciences industry, including pharmaceutical, biotechnology, medical device and related organizations. Its applications are designed to support functions across the product lifecycle, from research and clinical development through regulatory approval, manufacturing, quality management and commercial operations.

The company’s Veeva Vault platform includes applications for clinical data management, electronic trial management, regulatory information, quality processes, safety operations and commercial content management.